Enovis (NYSE: CFX)
Enovis Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Enovis Company Info
Enovis Corp. operates as a medical technology growth company. It develops clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The firm operates through the following segments: Medical Technology and Fabrication Technology. The Medical Technology segment develops, manufactures and distributes medical devices used for rehabilitation, pain management and physical therapy. The Fabrication Technology develops, manufactures and supplies consumable products and equipment. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Wilmington, DE.
News & Analysis
Why Colfax Got the Axe Today -- Down 16%
Investors fear the cost of an expansion into orthopedics.
Why Colfax Corporation Stock Dropped 9%
One earnings "beat" could be followed by a "miss."
Why Colfax Stock Got Crushed This Morning
Earnings meet estimates. Revenues don't.
Shares of Colfax Corporation Plunge 10% Despite Topping Estimates
Colfax's business is feeling pressure in its oil, gas, and mining markets.
Why Colfax Corp's Shares Plunged 14% Today
Third-quarter earnings weren't kind to Colfax Corp today.
Why Colfax May Be About to Take Off
Don't just ask, "How much inventory?" Ask, "What kind?"
Colfax Beats Analyst Estimates on EPS
Just the facts, Fool.
Coming Soon: Colfax Earnings
Checking expectations
Valuation
Earnings Transcripts
Colfax Corporation (CFX) Q2 2021 Earnings Call Transcript
CFX earnings call for the period ending June 30, 2021.
Colfax Corporation (CFX) Q2 2021 Earnings Call Transcript
CFX earnings call for the period ending June 30, 2021.
Colfax Corp (CFX) Q1 2021 Earnings Call Transcript
CFX earnings call for the period ending April 3, 2021.
Colfax Corp (CFX) Q4 2020 Earnings Call Transcript
CFX earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.